Atazanavir Sulphate
₹150.00
Applications
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV).
Description
Atazanavir Sulfate is a sulfate salt form of atazanavir, an aza-dipeptide analogue with a bis-aryl substituent on the (hydroxethyl)hydrazine moiety with activity against both wild type and mutant forms of HIV protease. Atazanavir does not elevate serum lipids, a common problem with other protease inhibitors.
Preparation
According to an aspect of the present invention, there is provided a process for the preparation of Compound (A) that comprises preparing atazanavir sulphate by treating atazanavir base (Compound (II)) with sulphuric acid in a combination of solvents, and isolating Compound (A).
Chemical Properties
Atazanavir sulfate is a white to pale yellow crystalline powder with low solubility in water, known for its antiviral properties, and is a vital component in the treatment of HIV infection.
Definition
Atazanavir sulfate is a sulfated derivative of atazanavir, a protease inhibitor used in the treatment of HIV/AIDS by inhibiting the HIV protease enzyme.
Description
| Product Name | Atazanavir Sulphate |
| Brand | indian |
| Country of Origin | Made in India |
| Usage | Pharma |
| Formula | C38H54N6O11S |
| Molar Mass | 704.856 g/mol |
| CAS ID | 198904-31-3 |
| Elimination half-life | 6.5 hrs |
| Bioavailability | 68% |
| Molecular Weight | 802.94 |
| Melting point | 195.0°, or acetone; mp 198-199° (dec) |
| alpha | D22 -46.1° (c = 1 in 1:1 CH3OH/H2O, pH = 2.6) |
| storage temp | under inert gas (nitrogen or Argon) at 2-8°C |
| solubility | ≥28.7 mg/mL in DMSO with gentle warming; insoluble in H2O; ≥4.05 mg/mL in EtOH with gentle warming and ultrasonic |
| form | Powder |
| Packaging Size | As Per Requirement |
Our Export Location as a Atazanavir Sulphate Manufacturer, Supplier, Exporter, Stockist from India.
 Afghanistan
|
 Bosnia and Herzegovina
|
 Cote d’Ivoire
|
 Schaumburg-Lippe*
|
 India
|
Albania
Algeria
Andorra
Angola
Antigua and Barbuda
Argentina
Armenia
Australia
Austria
Austrian Empire
Azerbaijan
Baden
Bahamas
Bahrain
Bangladesh
Barbados
Bavaria
Belarus
Belgium
Belize
Benin (Dahomey)
Bolivia
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Mauritania
Mauritius
Mecklenburg-Schwerin
Mecklenburg-Strelitz
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Botswana
Brazil
Brunei
Brunswick and Lüneburg
Bulgaria
Burkina Faso 
Burma
Burundi
Cabo Verde
Cambodia
Cameroon
Canada
Cayman Islands
Central African Republic
Central American Federation
Chad
Chile
China
Colombia
Comoros
Congo Free State
Costa Rica
Morocco
Mozambique
Namibia
Nassau
Nauru
Nepal
Netherlands
New Zealand
Nicaragua
Niger
Nigeria
North German Confederation
North German Union
North Macedonia
Norway
Oldenburg
Oman
Orange Free State
Pakistan
Palau
Panama
Papal States
Croatia
Cuba
Cyprus
Czechia
Democratic Republic of the Congo
Denmark
Djibouti
Dominica
Dominican Republic
Duchy of Parma
East Germany
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Eswatini
Ethiopia
Federal Government of Germany
Fiji
Papua New Guinea
Paraguay
Peru
Philippines
Piedmont-Sardinia
Poland
Portugal
Qatar
Republic of Genoa*
Republic of Korea (South Korea)
Republic of the Congo
Romania
Russia
Rwanda
Saint Kitts and Nevis
Saint Lucia
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Finland
France
Gabon
Gambia
Georgia
Germany
Ghana
Grand Duchy of Tuscany
Greece
Grenada
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Hanover
Hanseatic Republics
Hawaii
Hesse
Holy See
Honduras
Hungary
Iceland
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Texas
Thailand
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kingdom of Serbia/Yugoslavia
Kiribati
Korea
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Lew Chew (Loochoo)
Timor-Leste
Togo
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Tuvalu
Two Sicilies*
Uganda
Ukraine
Union of Soviet Socialist Republics*
United Arab Emirates
United Kingdom
Uruguay
Uzbekistan
Vanuatu
Venezuela
Vietnam
Württemberg*
Yemen
Zambia
ZimbabweRelated products
-
- Sale!
- API and intermediate
Etoricoxib
- ₹10,000.00
-
- Sale!
- API and intermediate
Eptifibatide
- ₹9,450.00
-
- Sale!
- API and intermediate
Indapamide
- ₹200.00
Reviews
There are no reviews yet.